News
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
BerGenBio ASA: Notice of Annual General Meeting
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients
BerGenBio announces advancement of its strategic review
BerGenBio Fourth Quarter Results 2024
BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives
BerGenBio ASA: Invitation to fourth quarter 2024 results webcast
BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial